FDA Ephedrine Rule Cost-Benefit Analysis Needs Further Explanation - GAO
This article was originally published in The Tan Sheet
Executive Summary
FDA should be required to better explain the factors used in its cost-benefit analysis of the expected effects of the ephedrine proposed rule, the General Accounting Office states in a report on the rule released Aug. 4.
You may also be interested in...
FDA Ephedrine Adverse Event Data Questioned By GAO
FDA's scientific justification for its proposed rule restricting the use of ephedrine alkaloids in dietary supplements is "open to question," GAO says in a report on the ephedrine proposed rule issued Aug. 4.
FDA Ephedrine Adverse Event Data Questioned By GAO
FDA's scientific justification for its proposed rule restricting the use of ephedrine alkaloids in dietary supplements is "open to question," GAO says in a report on the ephedrine proposed rule issued Aug. 4.
FDA Ephedrine Adverse Event Data Questioned By GAO
FDA's scientific justification for its proposed rule restricting the use of ephedrine alkaloids in dietary supplements is "open to question," GAO says in a report on the ephedrine proposed rule issued Aug. 4.